Charles Schwab
OYST

Charles Schwab’s Oyster Point Pharma, Inc. Common Stock OYST Stock Holding History

Charles Schwab’s Portfolio OYST Stock Details OYST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-33,139
Closed -$386K – 3701
2022
Q1 		$386K Buy
33,139
+5,593
+20% +$66.6K ﹤0.01% 3156
2021
Q4 		$503K Hold
27,546
– – ﹤0.01% 3145
2021
Q3 		$327K Sell
27,546
-55,418
-67% -$807K ﹤0.01% 3249
2021
Q2 		$1.43M Buy
82,964
+10,036
+14% +$191K ﹤0.01% 2817
2021
Q1 		$1.33M Buy
72,928
+2,917
+4% +$61.2K ﹤0.01% 2762
2020
Q4 		$1.32M Buy
70,011
+1,303
+2% +$28.1K ﹤0.01% 2698
2020
Q3 		$1.45M Buy
68,708
+53,876
+363% +$1.26M ﹤0.01% 2588
2020
Q2 		$429K Buy
14,832
+2,833
+24% +$85.4K ﹤0.01% 2897
2020
Q1 		$420K Hold
11,999
– – ﹤0.01% 2774
2019
Q4 		$294K Buy
+11,999
New +$211K ﹤0.01% 2979

Other funds holding OYST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
TAM
Telemark Asset Management Boston, Massachusetts $1.08B AUM 70.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Charles Schwab's OYST Position: Q2 2022 in Review

Charles Schwab sold out of Oyster Point Pharma, Inc. Common Stock (OYST) in Q2 2022, closing a stake of 33,139 shares — an estimated $386K sold.

Charles Schwab first reported a position in OYST in Q4 2019 and held it in 10 quarters. The position peaked at $1.45M in Q3 2020. 61 funds tracked by Wall St. Rank hold OYST as of Q2 2022.

  • Charles Schwab reported no remaining Oyster Point Pharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Charles Schwab sold 33,139 Oyster Point Pharma, Inc. Common Stock shares in Q2 2022, an estimated $386K.
  • Charles Schwab first reported a position in Oyster Point Pharma, Inc. Common Stock in Q4 2019 and held it in 10 quarters.
  • Charles Schwab's Oyster Point Pharma, Inc. Common Stock position peaked at $1.45M in Q3 2020.
  • 61 funds tracked by Wall St. Rank held Oyster Point Pharma, Inc. Common Stock as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.